Sanofi, GSK tout 72% Omicron efficacy in PhIII trial of next-gen, bivalent shot — with an eye to year-end rollout
Sometimes, being late can give you an advantage.
That’s what Sanofi and GSK are trying to say as the Big Pharma partners report positive results …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
